GLP-1 Medications versus Bariatric Surgery

Many patients struggling with obesity see encouraging results from GLP-1 receptor agonists (GLP-1 RAs) and structured medical weight loss programs – at first. They can experience lower weight, increased energy, and even improved cardiometabolic health markers.

But for some, these improvements can plateau, or even reverse with the discontinuation of GLP-1 medications. Research shows that while these drugs can be highly effective for initial weight loss, the body’s biology often pushes back once treatment stops.

The decision to get off of GLP-1 therapy should be a medically guided one since stopping medication can trigger weight regain and affect obesity-related conditions. If you find that weight is creeping back or health concerns persist, bariatric surgery may be a more effective solution.

How Medications Work – and Why They Sometimes Don’t Last

GLP-1 RAs work by affecting hormones in the gut that regulate glucose, reduce appetite, and slow stomach emptying, which helps people feel full sooner. Clinical research confirms these medications can produce substantial weight loss while patients are on them.

Multiple studies indicate that once these medications are discontinued, weight regain is common and often rapid. Researchers have found that physiological adaptations, like increased hunger hormones (ghrelin) and decreased satiety signals (leptin, peptide YY), cause much of this rebound effect.1 People stopping medical weight loss programs could regain weight at roughly 4 pounds per month, returning to baseline within about one to two years.2 GLP-1 medications function more as temporary symptom management tools rather than permanent solutions

Why Not Stay on GLP-1 Medications?

The short answer is that it isn’t very realistic. Indefinite use is impractical, and this is why:

• Gastrointestinal symptoms such as nausea, constipation, and abdominal discomfort are common, particularly during dose escalation. In some patients, this discomfort does not subside.
• Regular weekly injections can become burdensome, requiring planning and mental bandwidth week after week that can lead to avoidance or missed doses.
• GLP-1 medications are costly, and insurance coverage can be inconsistent. Long-term expenses might become prohibitive and disrupt continuity of treatment.
• Long-term safety outcomes in real-world obesity treatment are still not well established, and more independent obesity-specific reviews are needed to fully understand the risks and benefits.3-4
• Routines shift, priorities evolve, and taking medication without a plan to taper off eventually can become mentally and emotionally exhausting, even for highly motivated patients.

Why Choose Bariatric Surgery – and When to Start the Conversation

GLP-1 medications are often a first-line option for patients who want to begin managing obesity with a less invasive approach. They can be highly effective at reducing appetite, helping control food cravings, and supporting modest weight loss.

Surgery, however, directly targets the mechanisms responsible for weight gain. It prompts a biological reset that yields more durable weight loss and improvements in conditions such as type 2 diabetes, hypertension, and sleep apnea, especially in patients with a higher BMI.

A conversation with a bariatric surgeon may be appropriate if weight continues to cycle despite consistent effort, if obesity-related conditions are becoming harder to control, or if long-term reliance on medications feels unsustainable. And seeking a surgical consultation does not commit you to surgery. What you get out of a consultation is clarity, education, and a fuller understanding of all available options.

Bariatric surgery is a strategic next step in managing obesity as the chronic condition it is – one that focuses on long-term health, stability, and quality of life.

Note: Deciding to stop GLP-1 medications should always be done in partnership with a healthcare provider.

Bariatric Specialists of the Carolinas focuses on helping individuals understand obesity as a serious, chronic disease and providing evidence-based surgical solutions to support long-term health. With a patient-centered approach, our practice combines education, clinical expertise, and compassionate care to guide patients before, during, and after weight loss surgery.

1. Kolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025). Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs. Cureus, 17(10), e94926. https://doi.org/10.7759/cureus.94926.
2. West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., Jebb, S. A., & Koutoukidis, D. A. (2026). Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 392. https://doi.org/10.1136/bmj-2025-085304.
3. Gamborg, M., Grand, M. K., Grell, K., Rosthøj, S., Pedersen-Bjergaard, U., Torp-Pedersen, C., & Mørch, L. S. (2025). Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial. The Lancet Regional Health – Europe, 55. https://doi.org/10.1016/j.lanepe.2025.101346.
4. Parkinson, M. (2025, October 30). GLP-1 drugs effective for weight loss, but more independent studies needed | Cochrane. Cochrane.org. https://www.cochrane.org/about-us/news/glp-1-drugs-effective-weight-loss-more-independent-studies-needed.